See more : Shanghai Construction Group Co., Ltd. (600170.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Avidity Biosciences, Inc. (RNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avidity Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KEBODA TECHNOLOGY Co., Ltd. (603786.SS) Income Statement Analysis – Financial Results
- PacRay International Holdings Limited (1010.HK) Income Statement Analysis – Financial Results
- Goldcliff Resource Corporation (GCN.V) Income Statement Analysis – Financial Results
- KRISHNA FILAMENT INDUSTRIES LI (KRIFILIND.BO) Income Statement Analysis – Financial Results
- Cosmos Group Co., Ltd. (002133.SZ) Income Statement Analysis – Financial Results
Avidity Biosciences, Inc. (RNA)
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9.56M | 9.22M | 9.33M | 6.79M | 2.32M | 379.00K |
| Cost of Revenue | 2.10M | 1.39M | 639.00K | 37.60M | 14.54M | 8.44M |
| Gross Profit | 7.46M | 7.84M | 8.69M | -30.82M | -12.22M | -8.06M |
| Gross Profit Ratio | 78.02% | 84.96% | 93.15% | -454.03% | -526.95% | -2,125.86% |
| Research & Development | 190.97M | 150.40M | 101.18M | 37.60M | 14.54M | 8.44M |
| General & Administrative | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Other Expenses | 0.00 | 4.92M | 42.00K | -78.00K | 0.00 | 0.00 |
| Operating Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Cost & Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Interest Income | 23.97M | 4.98M | 104.00K | 206.00K | 7.39M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 209.00K | 7.39M | 718.00K |
| Depreciation & Amortization | 2.10M | 1.39M | 639.00K | 373.00K | 597.00K | 383.00K |
| EBITDA | -233.50M | -177.53M | -117.41M | -43.77M | -16.75M | -10.12M |
| EBITDA Ratio | -2,442.44% | -1,939.65% | -1,265.83% | -652.38% | -732.38% | -2,668.87% |
| Operating Income | -235.60M | -178.91M | -118.05M | -44.28M | -17.33M | -10.50M |
| Operating Income Ratio | -2,464.41% | -1,939.65% | -1,265.83% | -652.38% | -747.39% | -2,769.92% |
| Total Other Income/Expenses | 23.38M | 4.92M | 42.00K | -78.00K | -7.40M | -718.00K |
| Income Before Tax | -212.22M | -174.00M | -118.01M | -44.36M | -24.73M | -11.22M |
| Income Before Tax Ratio | -2,219.87% | -1,886.33% | -1,265.38% | -653.53% | -1,066.58% | -2,959.37% |
| Income Tax Expense | 0.00 | -4.92M | -639.00K | -373.00K | 7.39M | 718.00K |
| Net Income | -212.22M | -169.08M | -117.37M | -43.98M | -32.12M | -11.93M |
| Net Income Ratio | -2,219.87% | -1,833.01% | -1,258.52% | -648.03% | -1,385.12% | -3,148.81% |
| EPS | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| EPS Diluted | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| Weighted Avg Shares Out | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
| Weighted Avg Shares Out (Dil) | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
Why Avidity Biosciences Zoomed to a 12% Gain This Week
The company's most promising pipeline program can continue unabated.
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the...
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-to-market commercial opportunities for its investigational candidates.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 23, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2024, the Human Capital Management Committee of...
3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity reported groundbreaking data in all three clinical programs addressing rare muscular dystrophies: myotonic dystrophy...
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Aug. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2024, the Human Capital Management Committee...
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public...
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
However, even with this massive appreciation, Wall Street analysts still see a solid upside in the stock. Based on recent analyst changes, the average price target is $62, implying an upside of 39%.
Source: https://incomestatements.info
Category: Stock Reports